Semper Paratus Acquisition (TVGN) Competitors $1.25 -0.01 (-0.40%) Closing price 07/3/2025 03:40 PM EasternExtended Trading$1.25 0.00 (0.00%) As of 07/3/2025 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVGN vs. MLYS, NRIX, ZYME, AVBP, PRAX, ARDX, LENZ, OCS, COGT, and SNDXShould you be buying Semper Paratus Acquisition stock or one of its competitors? The main competitors of Semper Paratus Acquisition include Mineralys Therapeutics (MLYS), Nurix Therapeutics (NRIX), Zymeworks (ZYME), ArriVent BioPharma (AVBP), Praxis Precision Medicines (PRAX), Ardelyx (ARDX), LENZ Therapeutics (LENZ), Oculis (OCS), Cogent Biosciences (COGT), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry. Semper Paratus Acquisition vs. Its Competitors Mineralys Therapeutics Nurix Therapeutics Zymeworks ArriVent BioPharma Praxis Precision Medicines Ardelyx LENZ Therapeutics Oculis Cogent Biosciences Syndax Pharmaceuticals Semper Paratus Acquisition (NASDAQ:TVGN) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk. Which has more risk and volatility, TVGN or MLYS? Semper Paratus Acquisition has a beta of -0.73, meaning that its share price is 173% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of -0.3, meaning that its share price is 130% less volatile than the S&P 500. Does the media favor TVGN or MLYS? In the previous week, Mineralys Therapeutics had 1 more articles in the media than Semper Paratus Acquisition. MarketBeat recorded 4 mentions for Mineralys Therapeutics and 3 mentions for Semper Paratus Acquisition. Semper Paratus Acquisition's average media sentiment score of 0.62 beat Mineralys Therapeutics' score of 0.47 indicating that Semper Paratus Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Semper Paratus Acquisition 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, TVGN or MLYS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSemper Paratus AcquisitionN/AN/A-$13.73MN/AN/AMineralys TherapeuticsN/AN/A-$177.81M-$3.73-3.89 Do analysts prefer TVGN or MLYS? Semper Paratus Acquisition currently has a consensus price target of $10.00, indicating a potential upside of 703.21%. Mineralys Therapeutics has a consensus price target of $32.25, indicating a potential upside of 122.03%. Given Semper Paratus Acquisition's stronger consensus rating and higher probable upside, analysts plainly believe Semper Paratus Acquisition is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Semper Paratus Acquisition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is TVGN or MLYS more profitable? Semper Paratus Acquisition's return on equity of 0.00% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Semper Paratus AcquisitionN/A N/A -934.56% Mineralys Therapeutics N/A -71.15%-65.71% Do institutionals and insiders believe in TVGN or MLYS? 84.5% of Mineralys Therapeutics shares are held by institutional investors. 73.2% of Semper Paratus Acquisition shares are held by company insiders. Comparatively, 25.6% of Mineralys Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummarySemper Paratus Acquisition beats Mineralys Therapeutics on 6 of the 11 factors compared between the two stocks. Get Semper Paratus Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVGN vs. The Competition Export to ExcelMetricSemper Paratus AcquisitionMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$228.03M$2.91B$5.54B$9.05BDividend YieldN/A2.44%5.24%4.02%P/E RatioN/A21.5627.4320.23Price / SalesN/A281.76416.89118.64Price / CashN/A42.7336.8958.07Price / Book-13.837.518.035.67Net Income-$13.73M-$55.05M$3.18B$249.13M7 Day Performance0.40%4.61%2.89%3.28%1 Month Performance-11.70%4.72%3.70%5.56%1 Year Performance77.86%5.92%36.02%21.12% Semper Paratus Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVGNSemper Paratus Acquisition3.9976 of 5 stars$1.25-0.4%$10.00+703.2%+81.5%$228.03MN/A0.003MLYSMineralys Therapeutics2.1724 of 5 stars$13.77+2.2%$32.25+134.2%+19.5%$878.56MN/A-3.6928NRIXNurix Therapeutics1.5204 of 5 stars$11.98+4.3%$30.18+151.9%-34.4%$875.95M$54.55M-4.28300Trending NewsUpcoming EarningsAnalyst RevisionZYMEZymeworks2.0015 of 5 stars$12.47-0.1%$21.00+68.4%+53.0%$867.63M$93.38M-8.31460Analyst ForecastAVBPArriVent BioPharma1.7483 of 5 stars$22.80-9.6%$39.29+72.3%+13.6%$862.84MN/A-6.0540High Trading VolumePRAXPraxis Precision Medicines3.1681 of 5 stars$41.63-1.7%$109.90+164.0%+18.2%$862.42M$8.12M-3.88110ARDXArdelyx4.4484 of 5 stars$3.63+2.0%$10.89+200.0%-19.3%$851.75M$333.61M-16.5090LENZLENZ Therapeutics1.3352 of 5 stars$30.48+1.8%$46.60+52.9%+84.2%$842.70MN/A-17.22110OCSOculis1.7678 of 5 stars$19.65+1.9%$35.33+79.8%+61.7%$841.81M$780K-7.442COGTCogent Biosciences2.6068 of 5 stars$7.26+0.4%$14.57+100.7%-8.9%$823.18MN/A-3.9580News CoverageAnalyst RevisionSNDXSyndax Pharmaceuticals3.1465 of 5 stars$9.19-3.1%$35.91+290.7%-53.8%$815.73M$23.68M-2.38110Positive News Related Companies and Tools Related Companies Mineralys Therapeutics Competitors Nurix Therapeutics Competitors Zymeworks Competitors ArriVent BioPharma Competitors Praxis Precision Medicines Competitors Ardelyx Competitors LENZ Therapeutics Competitors Oculis Competitors Cogent Biosciences Competitors Syndax Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVGN) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Semper Paratus Acquisition Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Semper Paratus Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TVGN Stock Alerts